vs

Side-by-side financial comparison of IDEX Corporation (IEX) and Organogenesis Holdings Inc. (ORGO). Click either name above to swap in a different company.

IDEX Corporation is the larger business by last-quarter revenue ($398.4M vs $225.6M, roughly 1.8× Organogenesis Holdings Inc.). IDEX Corporation runs the higher net margin — 30.1% vs 19.4%, a 10.8% gap on every dollar of revenue. On growth, Organogenesis Holdings Inc. posted the faster year-over-year revenue change (78.1% vs 16.7%). IDEX Corporation produced more free cash flow last quarter ($86.0M vs $34.8M). Over the past eight quarters, Organogenesis Holdings Inc.'s revenue compounded faster (43.2% CAGR vs -29.4%).

IDEX can refer to several things, including:International Defence Exhibition, a biennial arms and defense technology sales exhibition IDEX Corporation, a publicly listed company that makes fluidics systems and specialty engineered products Ideanomics, a publicly traded company that trades under the IDEX ticker symbol.

Organogenesis Holdings Inc. is a leading regenerative medicine firm specializing in developing and manufacturing advanced therapeutic products for wound care, surgical repair, sports medicine, and dermatology. It serves healthcare providers and patients primarily in the U.S. and select international markets, offering clinically validated solutions for unmet medical needs.

IEX vs ORGO — Head-to-Head

Bigger by revenue
IEX
IEX
1.8× larger
IEX
$398.4M
$225.6M
ORGO
Growing faster (revenue YoY)
ORGO
ORGO
+61.5% gap
ORGO
78.1%
16.7%
IEX
Higher net margin
IEX
IEX
10.8% more per $
IEX
30.1%
19.4%
ORGO
More free cash flow
IEX
IEX
$51.2M more FCF
IEX
$86.0M
$34.8M
ORGO
Faster 2-yr revenue CAGR
ORGO
ORGO
Annualised
ORGO
43.2%
-29.4%
IEX

Income Statement — Q2 FY2026 vs Q4 FY2025

Metric
IEX
IEX
ORGO
ORGO
Revenue
$398.4M
$225.6M
Net Profit
$120.0M
$43.7M
Gross Margin
99.9%
Operating Margin
43.3%
28.1%
Net Margin
30.1%
19.4%
Revenue YoY
16.7%
78.1%
Net Profit YoY
25.7%
469.5%
EPS (diluted)
$1.61
$0.31

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IEX
IEX
ORGO
ORGO
Q2 26
$398.4M
Q1 26
$407.7M
Q4 25
$899.1M
$225.6M
Q3 25
$878.7M
$150.9M
Q2 25
$865.4M
$101.0M
Q1 25
$814.3M
$86.7M
Q4 24
$862.9M
$126.7M
Q3 24
$798.2M
$115.2M
Net Profit
IEX
IEX
ORGO
ORGO
Q2 26
$120.0M
Q1 26
$128.3M
Q4 25
$128.3M
$43.7M
Q3 25
$127.8M
$21.6M
Q2 25
$131.6M
$-9.4M
Q1 25
$95.5M
$-18.8M
Q4 24
$123.2M
$7.7M
Q3 24
$119.1M
$12.3M
Gross Margin
IEX
IEX
ORGO
ORGO
Q2 26
99.9%
Q1 26
94.9%
Q4 25
43.1%
Q3 25
44.5%
Q2 25
45.3%
Q1 25
45.3%
72.6%
Q4 24
42.5%
75.5%
Q3 24
44.3%
76.7%
Operating Margin
IEX
IEX
ORGO
ORGO
Q2 26
43.3%
Q1 26
45.0%
Q4 25
20.4%
28.1%
Q3 25
21.1%
13.7%
Q2 25
21.7%
-12.5%
Q1 25
17.4%
-30.9%
Q4 24
19.2%
8.1%
Q3 24
21.0%
5.4%
Net Margin
IEX
IEX
ORGO
ORGO
Q2 26
30.1%
Q1 26
31.5%
Q4 25
14.3%
19.4%
Q3 25
14.5%
14.3%
Q2 25
15.2%
-9.3%
Q1 25
11.7%
-21.7%
Q4 24
14.3%
6.1%
Q3 24
14.9%
10.7%
EPS (diluted)
IEX
IEX
ORGO
ORGO
Q2 26
$1.61
Q1 26
$1.71
Q4 25
$1.71
$0.31
Q3 25
$1.70
$0.11
Q2 25
$1.74
$-0.10
Q1 25
$1.26
$-0.17
Q4 24
$1.61
$0.05
Q3 24
$1.57
$0.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IEX
IEX
ORGO
ORGO
Cash + ST InvestmentsLiquidity on hand
$586.2M
$93.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$4.0B
$300.1M
Total Assets
$6.9B
$598.7M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IEX
IEX
ORGO
ORGO
Q2 26
$586.2M
Q1 26
$580.0M
Q4 25
$580.0M
$93.7M
Q3 25
$593.8M
$63.7M
Q2 25
$568.2M
$73.1M
Q1 25
$594.1M
$110.0M
Q4 24
$620.8M
$135.6M
Q3 24
$633.2M
$94.3M
Total Debt
IEX
IEX
ORGO
ORGO
Q2 26
Q1 26
Q4 25
$1.8B
Q3 25
$1.9B
Q2 25
$1.9B
Q1 25
$2.0B
Q4 24
$2.0B
Q3 24
$2.1B
$62.3M
Stockholders' Equity
IEX
IEX
ORGO
ORGO
Q2 26
$4.0B
Q1 26
$4.0B
Q4 25
$4.0B
$300.1M
Q3 25
$4.0B
$255.1M
Q2 25
$4.0B
$233.2M
Q1 25
$3.9B
$242.9M
Q4 24
$3.8B
$262.9M
Q3 24
$3.8B
$278.5M
Total Assets
IEX
IEX
ORGO
ORGO
Q2 26
$6.9B
Q1 26
$6.9B
Q4 25
$6.9B
$598.7M
Q3 25
$7.0B
$509.8M
Q2 25
$6.9B
$461.1M
Q1 25
$6.8B
$467.4M
Q4 24
$6.7B
$497.9M
Q3 24
$7.0B
$446.3M
Debt / Equity
IEX
IEX
ORGO
ORGO
Q2 26
Q1 26
Q4 25
0.45×
Q3 25
0.48×
Q2 25
0.46×
Q1 25
0.50×
Q4 24
0.52×
Q3 24
0.55×
0.22×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IEX
IEX
ORGO
ORGO
Operating Cash FlowLast quarter
$39.4M
Free Cash FlowOCF − Capex
$86.0M
$34.8M
FCF MarginFCF / Revenue
21.6%
15.4%
Capex IntensityCapex / Revenue
4.4%
2.1%
Cash ConversionOCF / Net Profit
0.90×
TTM Free Cash FlowTrailing 4 quarters
$654.3M
$-24.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IEX
IEX
ORGO
ORGO
Q2 26
Q1 26
Q4 25
$209.5M
$39.4M
Q3 25
$203.5M
$3.1M
Q2 25
$161.7M
$-32.9M
Q1 25
$105.7M
$-19.9M
Q4 24
$172.6M
$10.9M
Q3 24
$205.3M
$8.7M
Free Cash Flow
IEX
IEX
ORGO
ORGO
Q2 26
$86.0M
Q1 26
$189.8M
Q4 25
$189.8M
$34.8M
Q3 25
$188.7M
$844.0K
Q2 25
$146.9M
$-36.5M
Q1 25
$91.4M
$-23.6M
Q4 24
$157.1M
$7.6M
Q3 24
$191.6M
$6.1M
FCF Margin
IEX
IEX
ORGO
ORGO
Q2 26
21.6%
Q1 26
46.6%
Q4 25
21.1%
15.4%
Q3 25
21.5%
0.6%
Q2 25
17.0%
-36.1%
Q1 25
11.2%
-27.2%
Q4 24
18.2%
6.0%
Q3 24
24.0%
5.3%
Capex Intensity
IEX
IEX
ORGO
ORGO
Q2 26
4.4%
Q1 26
15.6%
Q4 25
2.2%
2.1%
Q3 25
1.7%
1.5%
Q2 25
1.7%
3.6%
Q1 25
1.8%
4.2%
Q4 24
1.8%
2.7%
Q3 24
1.7%
2.2%
Cash Conversion
IEX
IEX
ORGO
ORGO
Q2 26
Q1 26
Q4 25
1.63×
0.90×
Q3 25
1.59×
0.14×
Q2 25
1.23×
Q1 25
1.11×
Q4 24
1.40×
1.43×
Q3 24
1.72×
0.71×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons